Chimeric antigen receptor T cell O&D-001 targeting BCMA and GPRC5D not checked

O&D BioTech Group CO., Limited

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Relapsed or Refractory Multiple Myeloma
Main trialPhase 1
“This study is a single-center, open and dose-escalation clinical study to evaluate the safety, tolerability, PK/PD characteristics and preliminary efficacy of the investigational drug O\&D-001 injection in the treatment of relapsed or refractory multiple myeloma.”In the company’s words, NCT07369895 on ClinicalTrials.gov

Other drugs for Relapsed or Refractory Multiple Myeloma

All 266 drugs for Relapsed or Refractory Multiple Myeloma

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Recruiting 28 Mar 2028 Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Chimeric antigen receptor T cell O&D-001 targeting BCMA and GPRC5D

Following is part of Solo: you see every change to Chimeric antigen receptor T cell O&D-001 targeting BCMA and GPRC5D the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in